• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of Ustekinumab for Active Perianal Fistulizing Crohn Disease: A Double-Center Cohort Study.

作者信息

Attauabi Mohamed, Burisch Johan, Seidelin Jakob Benedict

机构信息

Gastrounit, Medical Division, Copenhagen University Hospital, Hvidovre, Denmark.

Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, University of Copenhagen, Hvidovre Hospital, Denmark.

出版信息

Inflamm Bowel Dis. 2021 Feb 16;27(3):e37-e38. doi: 10.1093/ibd/izaa297.

DOI:10.1093/ibd/izaa297
PMID:33200769
Abstract
摘要

相似文献

1
Efficacy of Ustekinumab for Active Perianal Fistulizing Crohn Disease: A Double-Center Cohort Study.优特克单抗治疗活动性肛周瘘管型克罗恩病的疗效：一项双中心队列研究
Inflamm Bowel Dis. 2021 Feb 16;27(3):e37-e38. doi: 10.1093/ibd/izaa297.
2
Efficacy of ustekinumab for active perianal fistulizing Crohn's disease: a systematic review and meta-analysis of the current literature.乌司奴单抗治疗活动性肛周瘘管型克罗恩病的疗效：当前文献的系统评价和荟萃分析。
Scand J Gastroenterol. 2021 Jan;56(1):53-58. doi: 10.1080/00365521.2020.1854848. Epub 2020 Dec 2.
3
Reply to comments on: "Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease-A prospective nationwide multicenter cohort study".对以下评论的回复：“cx601（达维多斯特罗）治疗肛周瘘管型克罗恩病的疗效——一项全国性前瞻性多中心队列研究”
Wien Klin Wochenschr. 2024 May;136(9-10):297. doi: 10.1007/s00508-024-02363-z. Epub 2024 Apr 23.
4
Comments on: "Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease-A prospective nationwide multicenter cohort study".关于《cx601（达伐地司特）治疗肛周瘘管型克罗恩病的疗效——一项全国性前瞻性多中心队列研究》的评论
Wien Klin Wochenschr. 2024 May;136(9-10):295-296. doi: 10.1007/s00508-024-02359-9. Epub 2024 Apr 10.
5
Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging.采用磁共振成像对肛周瘘型克罗恩病的英夫利昔单抗治疗进行长期监测。
Clin Gastroenterol Hepatol. 2011 Feb;9(2):130-6. doi: 10.1016/j.cgh.2010.10.022. Epub 2010 Nov 5.
6
Ustekinumab is effective for perianal fistulising Crohn's disease: a real-world experience and systematic review with meta-analysis.乌司奴单抗治疗肛周克罗恩病瘘管的疗效：真实世界经验和系统评价及荟萃分析。
BMJ Open Gastroenterol. 2021 Dec;8(1). doi: 10.1136/bmjgast-2021-000702.
7
[Efficacy of infliximab combined with surgery in the treatment of perianal fistulizing Crohn disease].英夫利昔单抗联合手术治疗肛周瘘管型克罗恩病的疗效
Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Apr;16(4):323-7.
8
Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.乌司奴单抗治疗难治性克罗恩病：西班牙在大型多中心开放标签队列中的经验
Inflamm Bowel Dis. 2016 Jul;22(7):1662-9. doi: 10.1097/MIB.0000000000000842.
9
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCU.克罗恩病合并内瘘疾病患者的生物治疗长期疗效：GETECCU 的 BIOSCOPE 研究。
Am J Gastroenterol. 2023 Jun 1;118(6):1036-1046. doi: 10.14309/ajg.0000000000002152. Epub 2022 Dec 14.
10
Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.局部阿达木单抗注射治疗肛瘘型肛周克罗恩病的有效性和安全性：一项初步研究。
Dis Colon Rectum. 2012 Aug;55(8):870-5. doi: 10.1097/DCR.0b013e31825af532.

引用本文的文献

1
Refractory Crohn's Disease: Perspectives, Unmet Needs and Innovations.难治性克罗恩病：观点、未满足的需求与创新
Clin Exp Gastroenterol. 2024 Oct 10;17:261-315. doi: 10.2147/CEG.S434014. eCollection 2024.
2
Safety and Effectiveness of Ustekinumab for Crohn's Disease With Perianal Manifestations: Ad hoc Analysis Data From 1-Year Post-Marketing Surveillance Study in Japan.优特克单抗治疗克罗恩病肛周表现的安全性和有效性：来自日本上市后1年监测研究的特设分析数据。
Crohns Colitis 360. 2024 May 16;6(2):otae035. doi: 10.1093/crocol/otae035. eCollection 2024 Apr.
3
Crohn's Disease-Associated and Cryptoglandular Fistulas: Differences and Similarities.
克罗恩病相关性瘘管和隐窝腺性瘘管：差异与相似之处
J Clin Med. 2023 Jan 6;12(2):466. doi: 10.3390/jcm12020466.
4
Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.炎症性肠病中抗肿瘤坏死因子治疗无应答及应答丧失的管理
Front Med (Lausanne). 2022 Jun 15;9:897936. doi: 10.3389/fmed.2022.897936. eCollection 2022.
5
Successful Non-Operative Treatment of Enterovesical and Enterocutaneous Fistulas Due to Crohn's Disease.克罗恩病所致肠膀胱瘘和肠皮肤瘘的成功非手术治疗
Int Med Case Rep J. 2022 Mar 29;15:117-124. doi: 10.2147/IMCRJ.S346159. eCollection 2022.
6
Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy.优特克单抗治疗难治性克罗恩病患者的有效性：意大利一项多中心真实世界研究
Therap Adv Gastroenterol. 2022 Feb 14;15:17562848211072412. doi: 10.1177/17562848211072412. eCollection 2022.
7
Managing complex perianal disease after anti-TNF failure: Where to go next?抗TNF治疗失败后复杂肛周疾病的管理：下一步何去何从？
Curr Res Pharmacol Drug Discov. 2022 Jan 13;3:100081. doi: 10.1016/j.crphar.2022.100081. eCollection 2022.
8
Ustekinumab is effective for perianal fistulising Crohn's disease: a real-world experience and systematic review with meta-analysis.乌司奴单抗治疗肛周克罗恩病瘘管的疗效：真实世界经验和系统评价及荟萃分析。
BMJ Open Gastroenterol. 2021 Dec;8(1). doi: 10.1136/bmjgast-2021-000702.
9
How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data.如何优化乌司奴单抗治疗炎症性肠病：从临床试验和真实世界数据中吸取的经验教训。
Front Med (Lausanne). 2021 Jan 28;8:640813. doi: 10.3389/fmed.2021.640813. eCollection 2021.